150 related articles for article (PubMed ID: 14632776)
21. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
Kobrinsky NL; Sposto R; Shah NR; Anderson JR; DeLaat C; Morse M; Warkentin P; Gilchrist GS; Cohen MD; Shina D; Meadows AT
J Clin Oncol; 2001 May; 19(9):2390-6. PubMed ID: 11331317
[TBL] [Abstract][Full Text] [Related]
22. Immunological characterization of Hodgkin's and non-Hodgkin's lymphoma patients with high antibody titers against Epstein-Barr virus-associated antigens.
Masucci G; Mellstedt H; Masucci MG; Szigeti R; Ernberg I; Björkholm M; Tsukuda K; Henle G; Henle W; Pearson G
Cancer Res; 1984 Mar; 44(3):1288-300. PubMed ID: 6318984
[TBL] [Abstract][Full Text] [Related]
23. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
[TBL] [Abstract][Full Text] [Related]
24. Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma.
Kewalramani T; Nimer SD; Zelenetz AD; Malhotra S; Qin J; Yahalom J; Moskowitz CH
Bone Marrow Transplant; 2003 Oct; 32(7):673-9. PubMed ID: 13130314
[TBL] [Abstract][Full Text] [Related]
25. Rituximab immunotherapy for non-Hodgkin's lymphoma.
White CA
Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
[TBL] [Abstract][Full Text] [Related]
27. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines.
Carbone A; Gloghini A; Gattei V; Aldinucci D; Degan M; De Paoli P; Zagonel V; Pinto A
Blood; 1995 Feb; 85(3):780-9. PubMed ID: 7530508
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin's disease.
Gause A; Pohl C; Tschiersch A; Da Costa L; Jung W; Diehl V; Hasenclever D; Pfreundschuh M
Blood; 1991 May; 77(9):1983-8. PubMed ID: 1850308
[TBL] [Abstract][Full Text] [Related]
29. Assessing immunoglobulin heavy chain rearrangements in pediatric CD20-positive and CD20-negative classic Hodgkin's disease.
Shiramizu B; Perkins SL; Bergeron S; Lones M; Kelly K; Weiner M; Cairo MS
Clin Lymphoma; 2004 Dec; 5(3):184-9. PubMed ID: 15636694
[TBL] [Abstract][Full Text] [Related]
30. Morphological and immunohistochemical investigation of non-Hodgkin's lymphoma combined with Hodgkin's disease.
Hansmann ML; Fellbaum C; Hui PK; Lennert K
Histopathology; 1989 Jul; 15(1):35-48. PubMed ID: 2548946
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711
[TBL] [Abstract][Full Text] [Related]
32. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
33. Total registration of non-Hodgkin's lymphoma and Hodgkin's disease in Scotland: effect of deprivation and caseload on outcome.
Ewing JC; White JM; Rattray A; Lessells A; Mackie MJ
Hematology; 2003 Aug; 8(4):211-20. PubMed ID: 12911938
[TBL] [Abstract][Full Text] [Related]
34. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
[TBL] [Abstract][Full Text] [Related]
35. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease.
Younes A; Pro B; Robertson MJ; Flinn IW; Romaguera JE; Hagemeister F; Dang NH; Fiumara P; Loyer EM; Cabanillas FF; McLaughlin PW; Rodriguez MA; Samaniego F
Clin Cancer Res; 2004 Aug; 10(16):5432-8. PubMed ID: 15328181
[TBL] [Abstract][Full Text] [Related]
36. Clinical significance of elevated antinuclear antibody test in patients with Hodgkin's and Non-Hodgkin's lymphoma: a single center experience.
Altintas A; Cil T; Pasa S; Danis R; Kilinc I; Ayyildiz O; Muftuoglu E
Minerva Med; 2008 Feb; 99(1):7-14. PubMed ID: 18299692
[TBL] [Abstract][Full Text] [Related]
37. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
Lim SH; Hale G; Marcus RE; Waldmann H; Baglin TP
Br J Haematol; 1993 Jul; 84(3):542-4. PubMed ID: 8217808
[TBL] [Abstract][Full Text] [Related]
38. Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: a clinico-pathological and immuno-histochemical population-based study of 32 patients.
Amini RM; Enblad G; Sundström C; Glimelius B
Int J Cancer; 1997 May; 71(4):510-6. PubMed ID: 9178801
[TBL] [Abstract][Full Text] [Related]
39. Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.
Baig NA; Taylor RP; Lindorfer MA; Church AK; LaPlant BR; Pettinger AM; Shanafelt TD; Nowakowski GS; Zent CS
J Immunol; 2014 Feb; 192(4):1620-9. PubMed ID: 24431228
[TBL] [Abstract][Full Text] [Related]
40. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Blood; 1999 Jul; 94(2):429-33. PubMed ID: 10397709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
